Rallybio Corporation beat EPS estimates 0% of the time across 1 reported quarters (0 beats, 1 misses), averaging -21.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-1.09 | not reported | not reported | |
| Q1 FY26 | $-1.20 | $-1.46 | -21.7% | Miss |
Back to RLYB overview · RLYB holders · RLYB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.